{
    "organizations": [],
    "uuid": "e0d6f4741964c45ba1b8820eefd3856cb4e2b9b5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/idUSL8N1SH0PT",
    "ord_in_thread": 0,
    "title": "BRIEF-Rovi Updates Status Of The Pivotal PRISMA-3 Study Of DORIA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - LABORATORIOS FARMACEUTICOS ROVI SA :\n* SAID ON WEDNESDAY THAT AN INDEPENDENT DATA MONITORING COMMITTEE HAS RECOMMENDED TO CONTINUE THE CLINICAL TRIAL OF PRISMA-3 STUDY FOR THE ONCE-MONTHLY INJECTABLE FORMULATION OF RISPERIDONE ISM, DORIA, TO TREAT SCHIZOPHRENIA\n* RECOMMENDATION ALSO SAYS THAT AN INCREASE OF THE STUDY SAMPLE SIZE IS NOT NEEDED\n* COMPANY PLANS TO FILE A NEW DRUG APPLICATION (NDA), U.S. REGISTRATION DOSSIER FOR THE FOOD AND DRUG ADMINISTRATION (FDA) IN SECOND HALF OF 2019\nSource text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-10T13:23:00.000+03:00",
    "crawled": "2018-05-11T13:10:34.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "laboratorios",
        "farmaceuticos",
        "rovi",
        "sa",
        "said",
        "wednesday",
        "independent",
        "data",
        "monitoring",
        "committee",
        "recommended",
        "continue",
        "clinical",
        "trial",
        "study",
        "injectable",
        "formulation",
        "risperidone",
        "ism",
        "doria",
        "treat",
        "schizophrenia",
        "recommendation",
        "also",
        "say",
        "increase",
        "study",
        "sample",
        "size",
        "needed",
        "company",
        "plan",
        "file",
        "new",
        "drug",
        "application",
        "nda",
        "registration",
        "dossier",
        "food",
        "drug",
        "administration",
        "fda",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}